Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK9 | P45984 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | SORD | Q00796 | 7/20 | 0.32 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.32 |
| ▸ | PLG | P00747 | 1/20 | 0.31 |
| ▸ | PLAU | P00749 | 1/20 | 0.31 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.30 |
| ▸ | OGA | O60502 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008994 | 0.84 | MAPK9 (0.35) | MAPK9MAPK10POLBTRPV1 | |
| SCHEMBL558541 | 0.83 | MAPK9 (0.39) | MAPK9MAPK10POLBSORDTRPV1 | |
| SCHEMBL27523149 | 0.81 | MAPK9 (0.38) | MAPK9MAPK10POLBRPS6KA5OGA | |
| SCHEMBL29004177 | 0.80 | MAPK9 (0.35) | MAPK9MAPK10SORD | |
| SCHEMBL28404695 | 0.79 | MAPK9 (0.37) | MAPK9MAPK10POLBRPS6KA5OGA | |
| SCHEMBL20858109 | 0.79 | MAPK9 (0.37) | MAPK9MAPK10POLBRPS6KA5OGA | |
| SCHEMBL22065924 | 0.79 | MAPK9 (0.37) | MAPK9MAPK10POLBRPS6KA5OGA | |
| SCHEMBL2013406 | 0.79 | MAPK9 (0.37) | MAPK9MAPK10POLBRPS6KA5OGA | |
| SCHEMBL22576353 | 0.78 | MAPK9 (0.36) | MAPK9MAPK10POLBSORD | |
| SCHEMBL31728162 | 0.77 | SORD (0.36) | POLBSORDPLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118684633-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-09-24 | — | — | CN | disclosed |
| CN-113195441-B | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-12-01 | — | — | US | disclosed |
| CN-113195441-A | Androgen receptor modulators and methods of use thereof | 埃萨制药股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | ESSA PHARMA, INC. (CA) | 2021-07-13 | — | — | US | disclosed |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-08-06 | — | — | US | disclosed |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2020-08-06 | — | — | US | disclosed |
| WO-2020081999-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081999-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA, INC. (CA) | 2020-04-23 | — | — | WO | disclosed |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | ALTMAN MICHAEL D (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759366-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2013192125-A1 | PYRAZOLYL DERIVATIVES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-12-27 | — | — | WO | disclosed |
| US-8551984-B2 | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-08 | — | — | US | disclosed |
| CN-102858767-A | Aminopyrimidines as SYK inhibitors | MERCK SHARP & DOHME | 2013-01-02 | — | — | CN | disclosed |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-11-01 | — | — | US | disclosed |
| EP-2513098-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-10-24 | — | — | EP | disclosed |
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-10-06 | — | — | US | disclosed |
| WO-2011075515-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2011075517-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245205-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | MAPK9 956/4885MAPK10 1865/4885POLB 632/4885 |
| US-20200247763-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | MAPK9 1737/4885MAPK10 1097/4885POLB 3250/4885 |
| US-11059795-B2 | Androgen receptor modulators and methods for their use | AR, NR5A1, CYP17A1 | MAPK9 1737/4885MAPK10 1097/4885POLB 3250/4885 |
| US-20140243290-A1 | Aminopyrimidines as SYK Inhibitors | SYK, BTK, LCK | MAPK9 956/4885MAPK10 1865/4885POLB 632/4885 |
| US-20220380325-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, NR5A1, CYP17A1 | MAPK9 1737/4885MAPK10 1097/4885POLB 3250/4885 |
| US-20120277192-A1 | AMINOPYRIMIDINES AS SYK INHIBITORS | SYK, BTK, LCK | MAPK9 956/4885MAPK10 1865/4885POLB 632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.